GeneDx Holdings (WGS) Revenue (2020 - 2026)

GeneDx Holdings (WGS) has reported Revenue for 7 consecutive years, with $102.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Revenue rose 17.38% year-over-year to $102.3 million; the TTM figure through Mar 2026 stood at $442.7 million (up 34.09% YoY), while the FY2025 annual figure was $427.5 million, up 39.97% from the prior year.
• Revenue slipped to $102.3 million in Q1 2026 per WGS's latest filing, from $121.0 million in the prior quarter.
• Across five years, Revenue topped out at $121.0 million in Q4 2025 and bottomed at $36.2 million in Q2 2022.
• Historically, Revenue has averaged $74.9 million across 5 years, with a median of $70.5 million in 2024.
• Annual changes were most pronounced in 2022 — Revenue soared 92.77% — and 2023, when it sank 35.96%.
• GeneDx Holdings' Revenue stood at $61.4 million in 2022, then fell by 6.41% to $57.4 million in 2023, then soared by 66.57% to $95.6 million in 2024, then climbed by 26.5% to $121.0 million in 2025, then slipped by 15.48% to $102.3 million in 2026.
• Business Quant data shows WGS's Revenue at $102.3 million in Q1 2026, $121.0 million in Q4 2025, and $116.7 million in Q3 2025.